Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 26.17 -9.13% -2.63
RYTM closed down 9.13 percent on Tuesday, June 19, 2018, on 2.92 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical RYTM trend table...

Date Alert Name Type % Chg
Jun 19 Fell Below 50 DMA Bearish 0.00%
Jun 19 Below Lower BB Weakness 0.00%
Jun 19 Down 3 Days in a Row Weakness 0.00%
Jun 19 Down 4 Days in a Row Weakness 0.00%
Jun 19 Down 5 Days in a Row Weakness 0.00%
Jun 19 Gapped Down Weakness 0.00%
Jun 19 Lower Bollinger Band Touch Weakness 0.00%
Jun 18 New Downtrend Bearish -9.13%
Jun 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -9.13%
Jun 18 Wide Range Bar Range Expansion -9.13%

Older signals for RYTM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 34.99
52 Week Low 16.8
Average Volume 154,837
200-Day Moving Average 0.0
50-Day Moving Average 27.5506
20-Day Moving Average 31.656
10-Day Moving Average 31.992
Average True Range 2.1666
ADX 43.59
+DI 15.72
-DI 29.43
Chandelier Exit (Long, 3 ATRs ) 28.4902
Chandelier Exit (Short, 3 ATRs ) 31.7798
Upper Bollinger Band 35.5263
Lower Bollinger Band 27.7857
Percent B (%b) -0.21
BandWidth 24.452237
MACD Line 0.6145
MACD Signal Line 1.4852
MACD Histogram -0.8708
Fundamentals Value
Market Cap 682.36 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -8.36
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.16
Resistance 3 (R3) 30.31 29.12 29.50
Resistance 2 (R2) 29.12 28.11 29.05 29.27
Resistance 1 (R1) 27.65 27.48 27.06 27.50 29.05
Pivot Point 26.46 26.46 26.17 26.39 26.46
Support 1 (S1) 24.99 25.45 24.40 24.84 23.29
Support 2 (S2) 23.80 24.82 23.73 23.07
Support 3 (S3) 22.33 23.80 22.85
Support 4 (S4) 22.18